Robert Bessler Sells 6,442 Shares of LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 6,442 shares of LifeStance Health Group stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $7.00, for a total value of $45,094.00. Following the transaction, the director directly owned 1,378,954 shares of the company’s stock, valued at approximately $9,652,678. This represents a 0.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Robert Bessler also recently made the following trade(s):

• On Monday, December 15th, Robert Bessler sold 12,371 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total value of $86,597.00.
• On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.01, for a total value of $558,206.30.

LifeStance Health Group Price Performance

Shares of LifeStance Health Group stock traded up $0.11 on Friday, hitting $7.05. The company’s stock had a trading volume of 9,306,414 shares, compared to its average volume of 2,042,345. The company has a market capitalization of $2.74 billion, a P/E ratio of -235.00 and a beta of 1.13. LifeStance Health Group, Inc. has a 52-week low of $3.74 and a 52-week high of $8.30. The firm has a fifty day moving average price of $5.95 and a 200-day moving average price of $5.37. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Wednesday, November 5th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The company had revenue of $363.81 million during the quarter, compared to analysts’ expectations of $355.06 million. During the same quarter in the previous year, the business posted ($0.02) earnings per share. The firm’s quarterly revenue was up 16.3% compared to the same quarter last year. On average, equities research analysts expect that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LifeStance Health Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in LFST. Park Edge Advisors LLC purchased a new stake in shares of LifeStance Health Group during the 2nd quarter worth about $52,000. Bayesian Capital Management LP purchased a new position in LifeStance Health Group in the second quarter valued at approximately $52,000. Public Employees Retirement System of Ohio acquired a new position in LifeStance Health Group during the second quarter valued at approximately $70,000. Blair William & Co. IL purchased a new stake in LifeStance Health Group during the second quarter worth approximately $70,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of LifeStance Health Group in the third quarter worth $72,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LFST has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LifeStance Health Group in a research note on Monday. UBS Group raised their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Barclays assumed coverage on shares of LifeStance Health Group in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 price objective for the company. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Finally, BMO Capital Markets started coverage on LifeStance Health Group in a report on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.83.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.